{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:19:51Z","timestamp":1793387991938,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"am","delay-in-days":284,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20fk0108543h0001"],"award-info":[{"award-number":["20fk0108543h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20H00664"],"award-info":[{"award-number":["20H00664"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.dmpk.2021.100432","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T02:01:56Z","timestamp":1636682516000},"page":"100432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":144,"special_numbering":"C","title":["Adenovirus vector-based vaccine for infectious diseases"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1366-9662","authenticated-orcid":false,"given":"Fuminori","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-508X","authenticated-orcid":false,"given":"Masashi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2021.100432_bib1","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1099\/vir.0.000196","article-title":"Human mastadenovirus type 70: a novel, multiple recombinant species D mastadenovirus isolated from diarrhoeal faeces of a haematopoietic stem cell transplantation recipient","volume":"96","author":"Hage","year":"2015","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.dmpk.2021.100432_bib3","doi-asserted-by":"crossref","first-page":"15191","DOI":"10.1073\/pnas.261452898","article-title":"The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction","volume":"98","author":"Cohen","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.dmpk.2021.100432_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.dmpk.2021.100432_bib5","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1093\/emboj\/16.19.5998","article-title":"The role of the nuclear pore complex in adenovirus DNA entry","volume":"16","author":"Greber","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.dmpk.2021.100432_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.dmpk.2021.100432_bib7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1525-0016(03)00243-0","article-title":"Characterization of in\u00a0vitro and in\u00a0vivo gene transfer properties of adenovirus serotype 35 vector","volume":"8","author":"Sakurai","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib8","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.dmpk.2021.100432_bib9","doi-asserted-by":"crossref","first-page":"9183","DOI":"10.1128\/JVI.77.17.9183-9191.2003","article-title":"Adenovirus type 11 uses CD46 as a cellular receptor","volume":"77","author":"Segerman","year":"2003","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.dmpk.2021.100432_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1128\/JVI.74.1.42-48.2000","article-title":"Adenovirus type 37 uses sialic acid as a cellular receptor","volume":"74","author":"Arnberg","year":"2000","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib12","doi-asserted-by":"crossref","first-page":"eaax3567","DOI":"10.1126\/sciadv.aax3567","article-title":"Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor","volume":"5","author":"Baker","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.dmpk.2021.100432_bib13","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1128\/JVI.74.6.2567-2583.2000","article-title":"Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector","volume":"74","author":"Shayakhmetov","year":"2000","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/sj.gt.3301959","article-title":"Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector","volume":"10","author":"Sakurai","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib15","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1128\/jvi.70.10.6839-6846.1996","article-title":"Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism","volume":"70","author":"Krasnykh","year":"1996","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib16","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1128\/JVI.79.8.5090-5104.2005","article-title":"Development and assessment of human adenovirus type 11 as a gene transfer vector","volume":"79","author":"Stone","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib17","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1089\/10430349950018409","article-title":"Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells","volume":"10","author":"Nalbantoglu","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/hum.2007.040","article-title":"Downregulation of CD46 during muscle differentiation: implications for gene transfer to human skeletal muscle using group B adenoviruses","volume":"19","author":"Larochelle","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib20","first-page":"341","article-title":"Identification and quantification of complement regulator CD46 on normal human tissues","volume":"79","author":"Johnstone","year":"1993","journal-title":"Immunology"},{"key":"10.1016\/j.dmpk.2021.100432_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1099\/vir.0.81293-0","article-title":"Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors","volume":"87","author":"Verhaagh","year":"2006","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib22","doi-asserted-by":"crossref","first-page":"10219","DOI":"10.1074\/jbc.274.15.10219","article-title":"Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia","volume":"274","author":"Walters","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dmpk.2021.100432_bib23","doi-asserted-by":"crossref","first-page":"20793","DOI":"10.1074\/jbc.272.33.20793","article-title":"Membrane cofactor protein (CD46) is a basolateral protein that is not endocytosed. Importance of the tetrapeptide FTSL at the carboxyl terminus","volume":"272","author":"Maisner","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dmpk.2021.100432_bib24","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/1873-3468.13696","article-title":"Innate immunity to adenovirus: lessons from mice","volume":"593","author":"Atasheva","year":"2019","journal-title":"FEBS Lett"},{"key":"10.1016\/j.dmpk.2021.100432_bib25","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/jgm.964","article-title":"Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production","volume":"8","author":"Basner-Tschakarjan","year":"2006","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.dmpk.2021.100432_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.mt.6300031","article-title":"Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors","volume":"15","author":"Cerullo","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1089\/hum.2007.016","article-title":"Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors","volume":"18","author":"Yamaguchi","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib28","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.4049\/jimmunol.181.3.2134","article-title":"Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in\u00a0vivo","volume":"181","author":"Appledorn","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.dmpk.2021.100432_bib29","first-page":"376","article-title":"TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses","volume":"1","author":"Appledorn","year":"2009","journal-title":"J\u00a0Innate Immun"},{"key":"10.1016\/j.dmpk.2021.100432_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.685218","article-title":"Lactoferrin retargets human adenoviruses to TLR4 to induce an abortive NLRP3-associated pyroptotic response in human phagocytes","volume":"12","author":"Ch\u00e9neau","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.dmpk.2021.100432_bib31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.01597-10","article-title":"Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors","volume":"85","author":"Rhee","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib32","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature12306","article-title":"cGAS produces a 2\u2019-5\u2019-linked cyclic dinucleotide second messenger that activates STING","volume":"498","author":"Ablasser","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.dmpk.2021.100432_bib33","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1128\/JVI.00500-16","article-title":"Diminished innate antiviral response to adenovirus vectors in cGAS\/STING-deficient mice minimally impacts adaptive immunity","volume":"90","author":"Anghelina","year":"2016","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41423-020-00602-7","article-title":"Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors","volume":"18","author":"Onomoto","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.dmpk.2021.100432_bib35","doi-asserted-by":"crossref","first-page":"17286","DOI":"10.1073\/pnas.1009823107","article-title":"Induction of type I interferon by adenovirus-encoded small RNAs","volume":"107","author":"Yamaguchi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.dmpk.2021.100432_bib36","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/JVI.02160-10","article-title":"Adenovirus virus-associated RNAs induce type I interferon expression through a RIG-I-mediated pathway","volume":"85","author":"Minamitani","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbrc.2012.07.056","article-title":"Type-I IFN signaling is required for the induction of antigen-specific CD8(+) T cell responses by adenovirus vector vaccine in the gut-mucosa","volume":"425","author":"Shoji","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.dmpk.2021.100432_bib38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fimmu.2018.00124","article-title":"Humoral responses elicited by adenovirus displaying epitopes are induced independently of the infection process and shaped by the toll-like receptor\/MyD88 pathway","volume":"9","author":"Anchim","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.dmpk.2021.100432_bib39","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.4049\/jimmunol.1700698","article-title":"Priming and activation of inflammasome by canarypox virus vector ALVAC via the cGAS\/IFI16-STING-type I IFN pathway and AIM2 sensor","volume":"199","author":"Liu","year":"2017","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.dmpk.2021.100432_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature06664","article-title":"The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response","volume":"452","author":"Muruve","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.dmpk.2021.100432_bib41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/infdis\/jiu485","article-title":"Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans","volume":"211","author":"Baden","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.dmpk.2021.100432_bib42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.virol.2009.09.018","article-title":"Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge","volume":"395","author":"Park","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.dmpk.2021.100432_bib43","doi-asserted-by":"crossref","first-page":"109400","DOI":"10.1016\/j.celrep.2021.109400","article-title":"A\u00a0single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","volume":"36","author":"Bricker","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.dmpk.2021.100432_bib44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1128\/CVI.00010-12","article-title":"Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route","volume":"19","author":"Patterson","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.dmpk.2021.100432_bib45","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.dmpk.2021.100432_bib46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1126\/science.aax8819","article-title":"MAIT cell activation augments adenovirus vector vaccine immunogenicity","volume":"371","author":"Provine","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.dmpk.2021.100432_bib47","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1128\/JVI.02563-09","article-title":"Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes","volume":"84","author":"Kaufman","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib48","first-page":"218","article-title":"Mapping and role of T cell response in SARS-CoV-2-infected mice","author":"Zhuang","year":"2021","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.dmpk.2021.100432_bib49","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3389\/fimmu.2017.01456","article-title":"T\u00a0helper 17 promotes induction of antigen-specific gut-mucosal cytotoxic T lymphocytes following adenovirus vector vaccination","volume":"8","author":"Hemmi","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.dmpk.2021.100432_bib50","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.4049\/jimmunol.181.6.4188","article-title":"Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination","volume":"181","author":"Kaufman","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.dmpk.2021.100432_bib51","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1128\/JVI.78.23.13207-13215.2004","article-title":"Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5","volume":"78","author":"Holterman","year":"2004","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib52","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.dmpk.2021.100432_bib53","first-page":"351","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.dmpk.2021.100432_bib54","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib55","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1099\/vir.0.82079-0","article-title":"Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity","volume":"87","author":"Lemckert","year":"2006","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib56","doi-asserted-by":"crossref","first-page":"19985","DOI":"10.1073\/pnas.1014074107","article-title":"Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)","volume":"107","author":"Mallery","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.dmpk.2021.100432_bib57","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1128\/IAI.74.1.313-320.2006","article-title":"Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice","volume":"74","author":"Ophorst","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.dmpk.2021.100432_bib58","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.72.8.6875-6879.1998","article-title":"Circumvention of immunity to the adenovirus major coat protein hexon","volume":"72","author":"Roy","year":"1998","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib59","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.00866-09","article-title":"Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization","volume":"84","author":"Cheng","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib60","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.dmpk.2021.100432_bib61","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1128\/JVI.00821-09","article-title":"Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys","volume":"83","author":"Barouch","year":"2009","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jgm.1530","article-title":"Creation of a panel of vectors based on ape adenovirus isolates","volume":"13","author":"Roy","year":"2011","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.dmpk.2021.100432_bib63","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1089\/hum.1997.8.17-2103","article-title":"A\u00a0recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in\u00a0vivo","volume":"8","author":"Klonjkowski","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib64","doi-asserted-by":"crossref","first-page":"11603","DOI":"10.1128\/JVI.75.23.11603-11613.2001","article-title":"Replication-defective vector based on a chimpanzee adenovirus","volume":"75","author":"Farina","year":"2001","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040385","article-title":"A\u00a0novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.dmpk.2021.100432_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2019.05.008","article-title":"A\u00a0rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development","volume":"268","author":"Luo","year":"2019","journal-title":"Virus Res"},{"key":"10.1016\/j.dmpk.2021.100432_bib67","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1016\/j.biomaterials.2012.02.011","article-title":"A\u00a0hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X","volume":"33","author":"Matsui","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.dmpk.2021.100432_bib68","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.biomaterials.2010.10.060","article-title":"Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction","volume":"32","author":"Suzuki-Kouyama","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.dmpk.2021.100432_bib69","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1089\/10430349950018021","article-title":"PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in\u00a0vitro and in\u00a0vivo","volume":"10","author":"O'Riordan","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib70","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1368-8375(03)00047-2","article-title":"Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell lines","volume":"39","author":"Fukuhara","year":"2003","journal-title":"Oral Oncol"},{"key":"10.1016\/j.dmpk.2021.100432_bib71","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/mthe.2002.0545","article-title":"Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses","volume":"5","author":"Yotnda","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/mp900151k","article-title":"Anionic liposomes increase the efficiency of adenovirus-mediated gene transfer to coxsackie-adenovirus receptor deficient cells","volume":"7","author":"Zhong","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmpk.2021.100432_bib73","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2016.02.025","article-title":"Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy","volume":"89","author":"Ran","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.dmpk.2021.100432_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2021.05.015","article-title":"Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles","author":"Kakiuchi","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.574007","article-title":"Extracellular vesicles-mimetic encapsulation improves oncolytic viro-immunotherapy in tumors with low coxsackie and adenovirus receptor","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.dmpk.2021.100432_bib76","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.dmpk.2021.100432_bib77","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.dmpk.2021.100432_bib78","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype B HIV vaccine","volume":"5","author":"Gray","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.dmpk.2021.100432_bib79","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3018(20)30229-0","article-title":"Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1\/2a study","volume":"7","author":"Baden","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.dmpk.2021.100432_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dmpk.2021.100432_bib81","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(16)00080-5","article-title":"Anticipating the international spread of Zika virus from Brazil","volume":"387","author":"Bogoch","year":"2016","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.dmpk.2021.100432_bib82","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01722-17","article-title":"Recombinant chimpanzee adenovirus vaccine AdC7-M\/E protects against Zika virus infection and testis damage","volume":"92","author":"Xu","year":"2018","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.dmpk.2021.100432_bib83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/infdis\/jiy187","article-title":"Immunization with a novel human type 5 adenovirus-vectored vaccine expressing the premembrane and envelope proteins of Zika virus provides consistent and sterilizing protection in multiple immunocompetent and immunocompromised animal models","volume":"218","author":"Guo","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.dmpk.2021.100432_bib84","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A\u00a0double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an ad26-vectored anti-zika virus vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dmpk.2021.100432_bib85","first-page":"145","article-title":"Influenza vaccine for 2020-2021","volume":"62","year":"2020","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.dmpk.2021.100432_bib86","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.dmpk.2021.100432_bib87","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Van Kampen","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.dmpk.2021.100432_bib88","first-page":"131","article-title":"A\u00a0replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity","author":"Matsuda","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.dmpk.2021.100432_bib89","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/milmed\/160.6.300","article-title":"Adenovirus vaccines in the U.S. military","volume":"160","author":"Gaydos","year":"1995","journal-title":"Mil Med"},{"key":"10.1016\/j.dmpk.2021.100432_bib90","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3855\/jidc.6197","article-title":"Ebola from emergence to epidemic: the virus and the disease, global preparedness and perspectives","volume":"9","author":"Dhama","year":"2015","journal-title":"J\u00a0Infect Dev Ctries"},{"key":"10.1016\/j.dmpk.2021.100432_bib91","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(77)92000-1","article-title":"Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire","volume":"1","author":"Johnson","year":"1977","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.dmpk.2021.100432_bib92","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.vaccine.2020.08.050","article-title":"The Brighton Collaboration standardized template for collection of key information for risk\/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform","volume":"39","author":"Volkmann","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.dmpk.2021.100432_bib93","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.dmpk.2021.100432_bib94","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.dmpk.2021.100432_bib95","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.dmpk.2021.100432_bib96","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.dmpk.2021.100432_bib97","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.dmpk.2021.100432_bib98","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dmpk.2021.100432_bib99","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.dmpk.2021.100432_bib100","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/bloodadvances.2021004904","article-title":"A\u00a0case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2","volume":"5","author":"T\u00f8lb\u00f8ll S\u00f8rensen","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.dmpk.2021.100432_bib101","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dmpk.2021.100432_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102681","article-title":"Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines","volume":"122","author":"Hwang","year":"2021","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.dmpk.2021.100432_bib103","article-title":"ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","author":"van Doremalen","year":"2020","journal-title":"BioRxiv Prepr Serv Biol"},{"key":"10.1016\/j.dmpk.2021.100432_bib104","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.dmpk.2021.100432_bib105","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.dmpk.2021.100432_bib106","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet (Lond. Engl.)"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436721000537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436721000537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:57:28Z","timestamp":1761163048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436721000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":106,"alternative-id":["S1347436721000537"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2021.100432","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenovirus vector-based vaccine for infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2021.100432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100432"}}